34 results about "Allotransplantation" patented technology

A method for sequencing can be used to monitor a recipient of an allograft. A sample comprising nucleic acid molecules can be provided from the recipient of the allograft. A plurality of nucleic acid molecules can be isolated from the sample and amplified. The plurality of nucleic acid molecules can be subjected to one or more amplification reactions using a plurality of primers to generate a plurality of DNA molecules. The plurality of primers can target at least 100 independent polymorphisms. The DNA molecules, or derivatives thereof, can be sequenced. The method may not require genotyping of the recipient.

The disclosure provides lateral flow devices for detecting the presence or absence of methylated cIDNA and one or more protein(s) in a biological sample, such as urine or blood.

The present invention provides a human T cell lacking human leukocyte antigen (HLA) class I molecule and containing an exogenous ST6GALNAC6 gene, which has the following characteristics (a) and / or (b):(a) CD62L-positive and CD45RA-positive(b) a total ATP production rate of a human T cell-containing cell population of 400 pmol / min / 105 cells or more and a mitochondrial spare respiratory capacity of 40 pmol / min / 105 cells or more, 5-6 days after the application of T cell proliferation stimulation to the cell population. According to the present invention, a low-immunogenic human T cell that can remain stably in the body for a long period of time after transplantation is provided, and the development of a versatile CAR-T cell or TCR-T cell for allotransplantation becomes possible by using the human T cell.

The present disclosure relates to products and methods relating to transplant recipient antibodies bound to donor cell membrane fragments. Products and methods provided are used to separate and collect transplant recipient antibodies from donor cell membrane fragments, as well as to characterize the transplant recipient antibodies. The products and methods are useful for allotransplant or xenotransplant recipients.

Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) and / or mesenchymal stomal cells in other embodiments. Hydrogel carrier materials are also described herein.

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein the sample comprises a plurality of nucleic acid (NA) molecules, isolating the plurality of NA molecules from the sample, amplifying the plurality of NA molecules, subjecting the plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing the plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising a processor and a non-transitory computer readable storage medium encoded with a computer program that causes the processor to provide a sample, wherein the sample comprises a plurality of NA molecules, isolating the plurality of NA molecules from the sample, amplifying the plurality of NA molecules, subjecting the plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing the plurality of cDNA molecules or derivatives thereof.

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) or allograft rejection in subjects receiving donor cells. Also disclosed are methods enhancing regulatory T (Treg) cells for use in preventing GVHD. Also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the treated Treg cells. Also disclosed are enhanced Treg cells produced by the disclosed methods that have been engineered to express chimeric antigen receptor (CAR) polypeptide cells.

The present invention relates to a prognostic method for determining a probability of allograft rejection using an infrared spectroscopy-based method coupled with a machine learning model. The invention also refers to a method for determining a probability of efficiency of an allograft rejection rescue therapy.

Methods for producing allograft tissue by applying an antimicrobial solution to allograft tissue. The antimicrobial solution exhibits antimicrobial activity to make allograft resistant to microbial organisms, such as bacterium. Surface-modified tissue grafts prepared by these methods are also disclosed.

A cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host is, and methods for making and using the same is provided. The cell comprises a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and whose function is one or more of: to mitigate antigen presenting cell activation and function; to mitigate graft attacking leukocyte activity or cytolytic function; to mitigate macrophage cytolytic function and phagocytosis of allograft cells; to induce apoptosis in graft attacking leukocytes; to mitigate local inflammatory proteins; and to protect against leukocyte-mediated apoptosis.

To provide transplant tolerance induction with a carbodiimide-treated tolerizing vaccine.SOLUTION: The present disclosure is related to compositions and systems for inducing immune tolerance for transplanted cells, organs or tissues in a transplant recipient. Also provided herein are methods of making and administering tolerizing vaccines / regimens or preparatory regimens. In some aspects, disclosed herein is a preparatory regimen for allotransplantation or xenotransplantation, including: (a) apoptotic donor leukocytes fixed in a crosslinking agent; (b) an mTOR inhibitor; (c) an anti-tumor necrosis factor agent or an anti-tumor necrosis factor receptor agent; (d) an anti-interleukin 6 agent or an anti-interleukin 6 receptor agent; and (e) an anti-CD40 agent or an anti-CD40 ligand agent; where the preparatory regimen is for administration to a recipient of a transplant cell, tissue or organ.SELECTED DRAWING: None

The present disclosure generally relates to methods of inhibiting an immune response and an immune response involved in transplant rejection, such as an allograft transplant rejection. In particular, the invention relates to the use of specific enzyme inhibitors that can be used to treat transplant rejection and / or prolong the survival of transplanted tissue or organs, in particular allotransplanted tissue or organs.

The present disclosure relates to products and methods for crossmatching transplant donors and recipients. Products and methods provided are based on solid phase supports coated with transplant donor cell membrane fragments. The products and methods are useful in allotransplantation and xenotransplantation.

Compositions of matter and treatment protocols for reducing or completely avoiding the need for immune suppression in the context of allograft or xenograft transplantation. Use of mesenchymal stem cells, manipulated mesenchymal stem cells, iPSC derived mesenchymal stem cells, and products of said mesenchymal stem cells for promoting the process of immunological tolerance. In one embodiment the invention provides the use of third party “universal donor” iPSC gene edited mesenchymal stem cells to promote tolerance in context of a solid organ transplant such as renal, cardiac, hepatic or small intestine. In other embodiments endogenous mesenchymal stem cells in composite tissue allografts are activated and / expanded in order to promote tolerogenesis and reduced need for immune suppression.

The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein said sample comprises a plurality of nucleic acid (NA) molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising, a processor, and a non-transitory computer readable storage medium encoded with a computer program that causes said processor to providing a sample, wherein said sample comprises a plurality of NA molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof.

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein said sample comprises a plurality of nucleic acid (NA) molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising, a processor, and a non-transitory computer readable storage medium encoded with a computer program that causes said processor to providing a sample, wherein said sample comprises a plurality of NA molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof.

The present disclosure relates to methods of treating or reducing the risk of transplant rejection or increasing a duration of time before transplant rejection occurs in a subject in need thereof (e.g., a human) by administering an antagonist that targets CD40 or CD154, such as an anti-CD40 antibody or an antigen-binding fragment thereof (e.g., a humanized anti-CD40 antibody or antigen-binding fragment thereof. The transplant may be an allogeneic or xenogeneic transplant (e.g., a cell, tissue, or organ or portion thereof).

The invention belongs to the technical field of regenerative medicine, and discloses a method for differentiating an i PSC cell strain into melanocytes and application of the method, and the method comprises the following steps: firstly establishing an HLA monomer high-matching i PSC cell strain, and then establishing a method for effectively directionally differentiating into the melanocytes, so as to prepare the melanocytes on a large scale; the application is the application of the method for differentiating the i PSC cell strain into the melanocytes in the aspect of clinical white hair blackening by allograft transplantation. The melanocyte preparation method has the advantages of strong in-vitro amplification capability, high success rate and low preparation cost, and is beneficial to clinical popularization and application in the future.

There is disclosed a system and methods for safely and securely gripping osseous-based tissue during allograft processing. One embodiment includes a first forceps half pivotally coupled to a second forceps half, where the first and the second forceps halves combine to form a handle portion and a head portion. The handle portion may define a first longitudinal axis, and the head portion may define a second longitudinal axis that intersects the first longitudinal axis at a varying head angle. The first and the second halves move between an open position in which the first and second forceps halves at the head portion are separated and a closed position in which the first and second forceps halves at the head portion are together. The forceps may also include an open-biasing spring element attached between the first and second forceps halves and a selective locking mechanism. Other embodiments are also disclosed.

There is disclosed a system and methods for safely and securely gripping osseous-based tissue during allograft processing. One embodiment includes a first forceps half pivotally coupled to a second forceps half, where the first and the second forceps halves combine to form a handle portion and a head portion. The handle portion may define a first longitudinal axis, and the head portion may define a second longitudinal axis that intersects the first longitudinal axis at a varying head angle. The first and the second halves move between an open position in which the first and second forceps halves at the head portion are separated and a closed position in which the first and second forceps halves at the head portion are together. The forceps may also include an open-biasing spring element attached between the first and second forceps halves and a selective locking mechanism. Other embodiments are also disclosed.

Provided are a composition and method for allogeneic transplantation. Provided is an sgRNA combination targeting HLA class I genes, which can knock out HLA-A and HLA-B with high efficiency, and knock out HLA-C with low efficiency. The sgRNA combination can be used for preparing engineered cells with modified HLA class I genes, and the obtained engineered cells can be further used in the prevention and / or treatment of diseases such as cancer, infection or autoimmune diseases.

A method for identifying a renal allograft recipient's risk for developing fibrosis of the allograft and allograft loss is disclosed. The method includes identifying the allograft recipient as being at risk for fibrosis of the allograft and allograft loss when the expression level of one or more genes in a preselected gene signature set is altered relative to the expression level of the same one or more genes in a control blood specimen is indicative of the allograft recipient's risk of developing fibrosis of the allograft and allograft loss.

Methods of reducing allograft rejection or the risk of allograft rejection in a subject are described. The methods include metabolically labelling an allograft tissue or organ with a chemical tag (such as dinitrophenyl), transplanting the labelled tissue or organ, and administering to the transplant recipient T regulatory (Treg) cells expressing a chimeric antigen receptor (CAR) specific for the chemical tag. The CAR-expressing Treg cells are stimulated upon binding to the chemical tag displayed on the transplanted tissue or organ, leading to activation of the Treg cells and suppression of effector CD8+ T cells, thereby generating of an immunosuppressive tissue environment that reduces the risk of allograft rejection. Kits that include a chemical tag, engineered CAR Treg cells specific for the chemical tag, and / or a viral vector encoding a CAR specific for the chemical tag are also described.

The invention discloses a nano self-assembly body capable of reducing allograft rejection. The nano self-assembly body is a nano particle obtained by self-assembling an artesunate-mycophenolic acid ester self-assembly body prodrug and DSPE-PEG2000, wherein the artesunate-mycophenolic acid ester self-assembly body prodrug and the DSPE-PEG2000 are of the following structure. The invention also discloses a preparation method and application of the nano self-assembly body. In addition, the invention also discloses a structure and a preparation method of the artesunate-mycophenolate self-assembly prodrug. In the preparation process of the nano self-assembly, artesunate and mycophenolic acid ester are synthesized into a prodrug through esterification reaction, and then the prodrug is combined with DSPE-PEG2000 to prepare the nano drug. The nano-drug has the characteristic of accurately targeting the spleen, and can effectively remodel the immune microenvironment after transplantation. Through research and development of the nano-drug, the problem of toxic and side effects caused by long-term use of a traditional immunosuppressor and the problem of poor treatment effect of a natural small-molecule immunosuppressor are successfully solved, and the nano-drug shows extremely wide development prospects and huge potential in the field of future clinical application.

The present invention relates to methods for monitoring potential indications of allogeneic organ rejection by monitoring transplanted hair follicles from the same donor of a transplanted organ, and for performing or modifying immunosuppressive therapy to ameliorate or prevent the occurrence of acute or chronic organ rejection. The methods of the invention may also be used to select candidate allogeneic solid organ donors for recipients, as well as to improve the occurrence of acute rejection of transplanted allogeneic solid organs, such as kidneys.

Provided is a method for reducing or eliminating allograft rejection by using a thymus vaccine. The method comprises the following steps: expressing major histocompatibility complex (MHC) from a donor and / or grafting a thymus epithelial cell from a donor in the thymus tissue of a recipient by means of the thymus vaccine. The thymus vaccine includes a thymic gene vaccine and / or a thymocyte vaccine. The thymic gene vaccine is used for expressing an MHC antigen from the donor in the thymus of the recipient, and comprises: (1) a gene expression vector; and (2) polynucleotides separately encoding MHC class I molecules and MHC class II molecules of the donor. The thymocyte vaccine is prepared by the following steps: sorting by using an anti-Epcam antibody to give thymus epithelial cells. By establishing a convenient donor source, the limitations of allograft caused by MHC mismatch are overcome, thus helping solve the clinical problem of limited donor sources.

The invention provides an implantable device and method of monitoring wirelessly and continuously thermal conductivity and blood flow on the surface of a target region of a subject. The implantable device comprises a probe operably attached to the target region; and an electronic module coupled with the probe for wireless, real-time, and continuous measurements of physiological information of the target region.

A method for producing non-resorbable bone allografts having improved osteoconductivity and biocompatibility in regenerative dental and medical applications as compared with non-resorbable xenografts. The method comprises excising one or more bone allografts from a donor's body; freeze-drying the bone allografts; demineralizing the freeze-dried bone allografts; preserving and sterilizing the bone allografts; and thermal processing of the bone allografts at a temperature greater than about 300 degrees Celsius.

The invention discloses an allograft cornea stroma lens as well as a preparation method and application thereof, and relates to the technical field of cornea transplantation. The preparation method comprises the following steps: obtaining a corneal stroma lens material from a donor; the cornea stroma lens material is subjected to irradiation and high-low water pressure circulation cleaning, and a semi-finished cornea stroma lens product is obtained; performing low-temperature cryopreservation in sterile glycerol; selecting a proper semi-finished product of the cornea stroma lens, and refrigerating the semi-finished product of the cornea stroma lens at low temperature and rewarming; and soaking the reheated semi-finished cornea stroma lens product in separated platelet-rich serum, so that the platelet-rich serum is adsorbed on the surface of the semi-finished cornea stroma lens product to obtain the allograft cornea stroma lens. Clinical practice observation shows that the curative effect of the cornea stroma lens treated by the process on treatment of intractable macular pores is superior to that of similar surgical treatment using biological amnions. The vision retention of the patient after the operation by using the corneal stroma lens is higher than that after the operation by using the biological amniotic membrane.